Published in Hepatology on July 25, 2014
Assessing a microrNA panel in diagnosing early cholangiocarcinoma. Hepatology (2015) 1.07
Extracellular vesicle profiling and their use as potential disease specific biomarker. Front Immunol (2014) 1.05
MicroRNAs in bile vesicles: finding a trade-off for biomarker discovery. Hepatology (2015) 0.99
Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol (2016) 0.96
The fusion of two worlds: non-coding RNAs and extracellular vesicles--diagnostic and therapeutic implications (Review). Int J Oncol (2014) 0.93
MicroRNAs in Serum and Bile of Patients with Primary Sclerosing Cholangitis and/or Cholangiocarcinoma. PLoS One (2015) 0.84
Primary Sclerosing Cholangitis as a Premalignant Biliary Tract Disease: Surveillance and Management. Clin Gastroenterol Hepatol (2015) 0.82
Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Clin Exp Immunol (2016) 0.82
Overview of microRNA biology. Semin Liver Dis (2015) 0.82
Extracellular vesicles carry microRNA-195 to intrahepatic cholangiocarcinoma and improve survival in a rat model. Hepatology (2016) 0.82
Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy. Int J Nanomedicine (2016) 0.81
Non-coding RNAs in Exosomes: New Players in Cancer Biology. Curr Genomics (2015) 0.80
MicroRNAs in Cholangiopathies. Curr Pathobiol Rep (2014) 0.80
Extracellular vesicle noncoding RNA: new players in the diagnosis and pathogenesis of cholangiocarcinoma. Hepatology (2014) 0.80
MicroRNAs in the Cholangiopathies: Pathogenesis, Diagnosis, and Treatment. J Clin Med (2015) 0.79
Molecular diagnosis of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci (2014) 0.79
MicroRNAs and benign biliary tract diseases. Semin Liver Dis (2015) 0.78
Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy. World J Gastrointest Endosc (2016) 0.78
Exosomes: novel implications in diagnosis and treatment of gastrointestinal cancer. Langenbecks Arch Surg (2016) 0.76
Circulating MicroRNAs as Biomarkers in Biliary Tract Cancers. Int J Mol Sci (2016) 0.76
Extracellular vesicles in liver pathobiology: Small particles with big impact. Hepatology (2016) 0.76
What is the current role of endoscopy in primary sclerosing cholangitis? World J Gastrointest Endosc (2015) 0.76
Lin28 and let-7: roles and regulation in liver diseases. Am J Physiol Gastrointest Liver Physiol (2016) 0.75
A novel approach for selecting combination clinical markers of pathology applied to a large retrospective cohort of surgically resected pancreatic cysts. J Am Med Inform Assoc (2016) 0.75
Greater Biosynthetic Liver Dysfunction in Primary Sclerosing Cholangitis Suggests Co-existent or Impending Cholangiocarcinoma. J Clin Transl Hepatol (2016) 0.75
Extracellular RNA in aging. Wiley Interdiscip Rev RNA (2016) 0.75
In vivo assessment of bone marrow toxicity by gold nanoparticle-based bioconjugates in Crl:CD1(ICR) mice. Int J Nanomedicine (2016) 0.75
Reply: To PMID 21858175. Hepatology (2015) 0.75
Deregulated MicroRNAs in Biliary Tract Cancer: Functional Targets and Potential Biomarkers. Biomed Res Int (2016) 0.75
Extracellular vesicles in liver diseases. Am J Physiol Gastrointest Liver Physiol (2016) 0.75
Reply: To PMID 24497320. Hepatology (2015) 0.75
The real-time dynamic monitoring of microRNA function in cholangiocarcinoma. PLoS One (2014) 0.75
Emerging molecular targets and therapy for cholangiocarcinoma. World J Gastrointest Oncol (2017) 0.75
Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008) 33.65
Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res (2008) 20.59
Exosomes: extracellular organelles important in intercellular communication. J Proteomics (2010) 6.47
MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol (2011) 5.46
The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS One (2012) 3.14
Intercellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth. Hepatology (2011) 2.90
MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer (2009) 2.56
Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol (2011) 2.51
The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol (2000) 2.25
Isolation and characterization of RNA-containing exosomes. J Vis Exp (2012) 2.16
Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol Ther (2012) 2.15
Cholangiocarcinoma--controversies and challenges. Nat Rev Gastroenterol Hepatol (2011) 2.11
Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology (2009) 2.10
Real-time PCR-based analysis of the human bile microRNAome identifies miR-9 as a potential diagnostic biomarker for biliary tract cancer. PLoS One (2011) 1.98
Biliary exosomes influence cholangiocyte regulatory mechanisms and proliferation through interaction with primary cilia. Am J Physiol Gastrointest Liver Physiol (2010) 1.85
Liver cell-derived microparticles activate hedgehog signaling and alter gene expression in hepatic endothelial cells. Gastroenterology (2008) 1.84
Correlation of somatic mutation and expression identifies genes important in human glioblastoma progression and survival. Cancer Res (2011) 1.83
Exosomes and other microvesicles in infection biology: organelles with unanticipated phenotypes. Cell Microbiol (2010) 1.82
Why your new cancer biomarker may never work: recurrent patterns and remarkable diversity in biomarker failures. Cancer Res (2012) 1.69
The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci (2005) 1.63
Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol (2012) 1.55
Collections of simultaneously altered genes as biomarkers of cancer cell drug response. Cancer Res (2013) 1.23
Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI-TOF MS in malignant bile duct stricture. Hepatology (2006) 1.10
Whole genome RNA expression profiling of endoscopic biliary brushings provides data suitable for biomarker discovery in cholangiocarcinoma. J Hepatol (2011) 1.00
Technology assessment in the Coronary Artery Surgery Study. Int J Technol Assess Health Care (1991) 0.86
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
Pancreatic cancer. Lancet (2011) 8.54
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
Flexible transgastric peritoneoscopy: a novel approach to diagnostic and therapeutic interventions in the peritoneal cavity. Gastrointest Endosc (2004) 7.91
Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science (2009) 7.39
Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol (2006) 5.78
Minireview: Cyclin D1: normal and abnormal functions. Endocrinology (2004) 5.22
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet (2009) 5.14
Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med (2011) 5.03
Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res (2009) 4.92
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89
Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med (2011) 4.76
An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol (2004) 4.74
Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci U S A (2010) 4.47
Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet (2011) 4.38
Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol (2006) 4.22
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat (2011) 3.63
MODBASE: a database of annotated comparative protein structure models and associated resources. Nucleic Acids Res (2006) 3.56
Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A (2011) 3.51
Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol (2008) 3.51
Confocal laser endomicroscopy in Barrett's esophagus and endoscopically inapparent Barrett's neoplasia: a prospective, randomized, double-blind, controlled, crossover trial. Gastrointest Endosc (2009) 3.46
Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol (2003) 3.40
Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med (2004) 3.39
Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res (2004) 3.31
ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov (2011) 3.27
The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature (2012) 3.23
Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res (2003) 3.23
A genome-wide search identifies epigenetic silencing of somatostatin, tachykinin-1, and 5 other genes in colon cancer. Gastroenterology (2006) 3.20
Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg (2009) 3.15
Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell (2002) 3.12
Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol (2004) 3.10
Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst (2010) 3.08
A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol (2008) 3.02
Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol (2006) 3.01
Peroral transgastric endoscopic ligation of fallopian tubes with long-term survival in a porcine model. Gastrointest Endosc (2005) 2.98
Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol (2007) 2.98
Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet (2013) 2.91
Focus on pancreas cancer. Cancer Cell (2002) 2.82
Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology (2012) 2.74
MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res (2013) 2.71
Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology (2012) 2.69
Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology (2012) 2.68
Combining local-structure, fold-recognition, and new fold methods for protein structure prediction. Proteins (2003) 2.67
Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol (2006) 2.66
Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. Cancer Res (2005) 2.64
Transforming growth factor-beta1 induces an epithelial-to-mesenchymal transition state in mouse hepatocytes in vitro. J Biol Chem (2007) 2.62
The Human MitoChip: a high-throughput sequencing microarray for mitochondrial mutation detection. Genome Res (2004) 2.54
Relation of body composition, fat mass, and serum lipids to osteoporotic fractures and bone mineral density in Chinese men and women. Am J Clin Nutr (2006) 2.52
A high-fat diet and regulatory T cells influence susceptibility to endotoxin-induced liver injury. Hepatology (2007) 2.52
Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res (2003) 2.49
Blood urea nitrogen in the early assessment of acute pancreatitis: an international validation study. Arch Intern Med (2011) 2.46
SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res (2009) 2.44
MicroRNAs and epigenetics. FEBS J (2011) 2.44
Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res (2010) 2.39
Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov (2012) 2.39
Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization. J Vasc Interv Radiol (2006) 2.39
Effect of a retrograde-viewing device on adenoma detection rate during colonoscopy: the TERRACE study. Gastrointest Endosc (2010) 2.38
Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma. Cancer Biol Ther (2008) 2.38
The miR-106b-25 polycistron, activated by genomic amplification, functions as an oncogene by suppressing p21 and Bim. Gastroenterology (2009) 2.35
Prioritization of driver mutations in pancreatic cancer using cancer-specific high-throughput annotation of somatic mutations (CHASM). Cancer Biol Ther (2010) 2.33
Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet (2003) 2.33
SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene (2003) 2.32
EUS-based criteria for the diagnosis of chronic pancreatitis: the Rosemont classification. Gastrointest Endosc (2009) 2.32
Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing. Sci Transl Med (2013) 2.30
DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. Cancer Res (2006) 2.29
Patient readmission and mortality after colorectal surgery for colon cancer: impact of length of stay relative to other clinical factors. J Am Coll Surg (2012) 2.29
Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res (2012) 2.27
Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol (2007) 2.26
MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology (2009) 2.23
Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol (2002) 2.22
Intrahepatic cholangiocarcinoma: management options and emerging therapies. J Am Coll Surg (2013) 2.22
Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation. Mol Cell Biol (2003) 2.22
Endoscopic gastrojejunostomy with survival in a porcine model. Gastrointest Endosc (2005) 2.20
Inositol pyrophosphates inhibit Akt signaling, thereby regulating insulin sensitivity and weight gain. Cell (2010) 2.17
Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut (2012) 2.17
A DNA methylation fingerprint of 1628 human samples. Genome Res (2011) 2.16
A comparative evaluation of early stent occlusion among biliary conventional versus wing stents. Dig Dis Sci (2012) 2.15
Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol (2011) 2.13
Retracted Aberrant methylation of Reprimo in human malignancies. Int J Cancer (2005) 2.13
Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene (2005) 2.07
Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res (2002) 2.07
Solitary colorectal liver metastasis: resection determines outcome. Arch Surg (2006) 2.06
Limitations of claims and registry data in surgical oncology research. Ann Surg Oncol (2007) 2.06
Pancreatic cancer genetic epidemiology consortium. Cancer Epidemiol Biomarkers Prev (2006) 2.04
Concordant loss of MTAP and p16/CDKN2A expression in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a noninvasive precursor lesion. Mod Pathol (2005) 2.03
The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev (2007) 2.03